255
Views
0
CrossRef citations to date
0
Altmetric
Chronic Kidney Disease and Progression

Association between annual changes and visit-to-visit variability of serum uric acid and the kidney outcome in a general population

, , &
Article: 2367702 | Received 17 Dec 2023, Accepted 07 Jun 2024, Published online: 24 Jun 2024

References

  • Chen N, Wang W, Huang Y, et al. Community-based study on CKD subjects and the associated risk factors. Nephrol Dial Transplant. 2009;24(7):1–8. doi: 10.1093/ndt/gfn767.
  • Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–822. doi: 10.1016/S0140-6736(12)60033-6.
  • Wang S, Shu Z, Tao Q, et al. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Nephrology. 2011;16(8):767–776. doi: 10.1111/j.1440-1797.2011.01513.x.
  • Ueda H, Inoue K, Seki R, et al. Lower range of serum uric acid level increases risk of rapid decline of kidney function in young and middle-aged adults: the Yuport Medical Checkup Center Study. Clin Exp Nephrol. 2023;27(5):435–444. doi: 10.1007/s10157-023-02318-0.
  • Hassan W, Shrestha P, Sumida K, et al. Association of uric acid-lowering therapy with incident chronic kidney disease. JAMA Netw Open. 2022;5(6):e2215878. doi: 10.1001/jamanetworkopen.2022.15878.
  • Lee DY, Han K, Park S, et al. Glucose variability and the risks of stroke, myocardial infarction, and all-cause mortality in individuals with diabetes: retrospective cohort study. Cardiovasc Diabetol. 2020;19(1):144. doi: 10.1186/s12933-020-01134-0.
  • Nam GE, Kim W, Han K, et al. Body weight variability and the risk of cardiovascular outcomes and mortality in patients with type 2 diabetes: a nationwide cohort study. Diabetes Care. 2020;43(9):2234–2241. doi: 10.2337/dc19-2552.
  • Li Y, Li D, Song Y, et al. Visit-to-visit variability in blood pressure and the development of chronic kidney disease in treated general hypertensive patients. Nephrol Dial Transplant. 2020;35(10):1739–1746. doi: 10.1093/ndt/gfz093.
  • Xu Y, Dong S, Fu EL, et al. Long-term visit-to-visit variability in hemoglobin A1c and kidney-related outcomes in persons with diabetes. Am J Kidney Dis. 2023;82(3):267–278. doi: 10.1053/j.ajkd.2023.03.007.
  • Yan Y, Huang Y, Zhou D, et al. Visit-to-visit variability in total cholesterol correlates with the progression of renal function decline in a Chinese community-based hypertensive population. Kidney Blood Press Res. 2019;44(4):727–742. doi: 10.1159/000501367.
  • Tian X, Wang A, Zuo Y, et al. Visit-to-visit variability of serum uric acid measurements and the risk of all-cause mortality in the general population. Arthritis Res Ther. 2021;23(1):74. doi: 10.1186/s13075-021-02445-7.
  • Uhlig T, Karoliussen LF, Sexton J, et al. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study. Clin Rheumatol. 2022;41(12):3817–3823. doi: 10.1007/s10067-022-06416-4.
  • Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470. doi: 10.7326/0003-4819-130-6-199903160-00002.
  • Johnson RJ, Sanchez Lozada LG, Lanaspa MA, et al. Uric acid and chronic kidney disease: still more to do. Kidney Int Rep. 2023;8(2):229–239. doi: 10.1016/j.ekir.2022.11.016.
  • Yano Y, Reis JP, Lewis CE, et al. Association of blood pressure patterns in young adulthood with cardiovascular disease and mortality in middle age. JAMA Cardiol. 2020;5(4):382–389. doi: 10.1001/jamacardio.2019.5682.
  • Nwabuo CC, Yano Y, Moreira HT, et al. Association between visit-to-visit blood pressure variability in early adulthood and myocardial structure and function in later life. JAMA Cardiol. 2020;5(7):795–801. doi: 10.1001/jamacardio.2020.0799.
  • Oishi E, Ohara T, Sakata S, et al. Day-to-day blood pressure variability and risk of dementia in a general Japanese elderly population: the Hisayama study. Circulation. 2017;136(6):516–525. doi: 10.1161/CIRCULATIONAHA.116.025667.
  • Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–663. doi: 10.1001/archinte.164.6.659.
  • Sharaf El Din UAA, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res. 2023;8(5):537–548.
  • Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729–1741; discussion 1741. doi: 10.1097/HJH.0000000000000701.
  • Kamei K, Konta T, Hirayama A, et al. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant. 2014;29(12):2286–2292. doi: 10.1093/ndt/gfu256.
  • Bellomo G, Venanzi S, Verdura C, et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56(2):264–272. doi: 10.1053/j.ajkd.2010.01.019.
  • Kuo CF, Luo SF, See LC, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol. 2011;40(2):116–121. doi: 10.3109/03009742.2010.507218.
  • Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLOS One. 2019;14(8):e0220532. doi: 10.1371/journal.pone.0220532.
  • Lim SS, Yang YL, Chen SC, et al. Association of variability in uric acid and future clinical outcomes of patient with coronary artery disease undergoing percutaneous coronary intervention. Atherosclerosis. 2020;297:40–46. doi: 10.1016/j.atherosclerosis.2020.01.025.
  • Ceriello A, De Cosmo S, Rossi MC, et al. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes Obes Metab. 2017;19(11):1570–1578. doi: 10.1111/dom.12976.
  • Shen J, Zhu J, Si S, et al. Uric acid fluctuation had no effect on renal function among gout patients. Nutr Metab Cardiovasc Dis. 2020;30(10):1833–1839. doi: 10.1016/j.numecd.2020.06.008.
  • Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res. 2013;36(7):650–654. doi: 10.1038/hr.2013.11.
  • Rathmann W, Haastert B, Icks A, et al. Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. Eur J Epidemiol. 2007;22(7):439–445. doi: 10.1007/s10654-007-9132-3.
  • Kuwabara M, Bjornstad P, Hisatome I, et al. Elevated serum uric acid level predicts rapid decline in kidney function. Am J Nephrol. 2017;45(4):330–337. doi: 10.1159/000464260.
  • Kuo CF, See LC, Yu KH, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatol Oxf Engl. 2013;52(1):127–134. doi: 10.1093/rheumatology/kes223.
  • Li M, Ye ZC, Li CM, et al. Low serum uric acid levels increase the risk of all-cause death and cardiovascular death in hemodialysis patients. Ren Fail. 2020;42(1):315–322. doi: 10.1080/0886022X.2020.1745234.
  • Matsukuma Y, Masutani K, Tanaka S, et al. A J-shaped association between serum uric acid levels and poor renal survival in female patients with IgA nephropathy. Hypertens Res. 2017;40(3):291–297. doi: 10.1038/hr.2016.134.
  • Braga TT, Forni MF, Correa-Costa M, et al. Soluble uric acid activates the NLRP3 inflammasome. Sci Rep. 2017;7(1):39884. doi: 10.1038/srep39884.